| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 88 | 2023 | 398 | 19.990 |
Why?
|
| Catheter Ablation | 39 | 2022 | 220 | 10.020 |
Why?
|
| Heart Conduction System | 36 | 2021 | 270 | 8.630 |
Why?
|
| Pulmonary Veins | 30 | 2022 | 107 | 6.110 |
Why?
|
| Heart Atria | 33 | 2022 | 171 | 5.860 |
Why?
|
| Vagus Nerve Stimulation | 18 | 2023 | 65 | 5.550 |
Why?
|
| Autonomic Nervous System | 23 | 2024 | 110 | 5.390 |
Why?
|
| Ganglia, Autonomic | 18 | 2018 | 55 | 5.040 |
Why?
|
| Vagus Nerve | 16 | 2022 | 106 | 4.530 |
Why?
|
| Dogs | 54 | 2020 | 504 | 4.180 |
Why?
|
| Heart Rate | 19 | 2024 | 374 | 4.180 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 24 | 2019 | 96 | 3.530 |
Why?
|
| Arrhythmias, Cardiac | 13 | 2024 | 163 | 3.510 |
Why?
|
| Electrocardiography | 22 | 2024 | 391 | 3.470 |
Why?
|
| Heart | 14 | 2024 | 219 | 3.250 |
Why?
|
| Tachycardia, Ventricular | 8 | 2020 | 60 | 3.180 |
Why?
|
| Autonomic Denervation | 8 | 2022 | 19 | 3.070 |
Why?
|
| Anti-Arrhythmia Agents | 12 | 2021 | 117 | 2.610 |
Why?
|
| Action Potentials | 18 | 2018 | 194 | 2.530 |
Why?
|
| Body Surface Potential Mapping | 8 | 2020 | 24 | 2.530 |
Why?
|
| Atrial Appendage | 7 | 2023 | 31 | 2.290 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 5 | 2020 | 25 | 2.220 |
Why?
|
| Electric Stimulation | 16 | 2015 | 253 | 2.200 |
Why?
|
| Cardiac Pacing, Artificial | 14 | 2019 | 146 | 2.170 |
Why?
|
| Sympathectomy | 5 | 2021 | 16 | 2.140 |
Why?
|
| Animals | 75 | 2020 | 9962 | 1.970 |
Why?
|
| Tachycardia, Supraventricular | 4 | 2022 | 23 | 1.730 |
Why?
|
| Disease Models, Animal | 22 | 2020 | 1394 | 1.680 |
Why?
|
| Autonomic Pathways | 5 | 2018 | 16 | 1.610 |
Why?
|
| Male | 55 | 2024 | 12875 | 1.530 |
Why?
|
| Humans | 86 | 2024 | 26846 | 1.530 |
Why?
|
| Sympathetic Nervous System | 4 | 2021 | 64 | 1.500 |
Why?
|
| Atropine | 9 | 2017 | 47 | 1.460 |
Why?
|
| Ganglion Cysts | 4 | 2012 | 8 | 1.460 |
Why?
|
| Acetylcholine | 9 | 2017 | 73 | 1.440 |
Why?
|
| Bradycardia | 2 | 2022 | 17 | 1.370 |
Why?
|
| Calcium Chloride | 2 | 2021 | 6 | 1.370 |
Why?
|
| Middle Aged | 35 | 2024 | 6820 | 1.350 |
Why?
|
| Muscarinic Antagonists | 3 | 2017 | 14 | 1.290 |
Why?
|
| Heart Failure | 6 | 2024 | 232 | 1.270 |
Why?
|
| Ligaments | 4 | 2020 | 22 | 1.180 |
Why?
|
| Female | 41 | 2024 | 14463 | 1.130 |
Why?
|
| Myocardial Ischemia | 4 | 2017 | 73 | 1.100 |
Why?
|
| Treatment Outcome | 23 | 2023 | 2264 | 1.080 |
Why?
|
| Accessory Atrioventricular Bundle | 2 | 2018 | 17 | 1.070 |
Why?
|
| Smartphone | 2 | 2017 | 58 | 1.030 |
Why?
|
| Atrioventricular Node | 3 | 2018 | 69 | 1.020 |
Why?
|
| Mobile Applications | 2 | 2017 | 58 | 1.020 |
Why?
|
| Postoperative Complications | 3 | 2021 | 604 | 1.020 |
Why?
|
| Renal Artery | 2 | 2016 | 15 | 1.010 |
Why?
|
| Aged | 21 | 2024 | 5166 | 0.940 |
Why?
|
| Vena Cava, Superior | 3 | 2017 | 27 | 0.930 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2011 | 65 | 0.890 |
Why?
|
| Electric Stimulation Therapy | 4 | 2024 | 56 | 0.880 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 63 | 0.870 |
Why?
|
| Coronary Artery Bypass | 2 | 2021 | 66 | 0.830 |
Why?
|
| Nerve Net | 3 | 2012 | 105 | 0.830 |
Why?
|
| Botulinum Toxins | 3 | 2018 | 10 | 0.820 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2014 | 38 | 0.790 |
Why?
|
| Pericardium | 4 | 2020 | 47 | 0.770 |
Why?
|
| Potassium Channels | 10 | 2001 | 20 | 0.760 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2020 | 33 | 0.750 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 14 | 0.730 |
Why?
|
| Atrial Function | 2 | 2011 | 22 | 0.710 |
Why?
|
| Catheters | 1 | 2020 | 23 | 0.710 |
Why?
|
| Refractory Period, Electrophysiological | 4 | 2017 | 21 | 0.710 |
Why?
|
| Denervation | 2 | 2020 | 10 | 0.710 |
Why?
|
| Mitral Valve | 2 | 2022 | 58 | 0.690 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 43 | 0.670 |
Why?
|
| Stellate Ganglion | 5 | 2017 | 21 | 0.660 |
Why?
|
| Algorithms | 3 | 2016 | 419 | 0.660 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2011 | 57 | 0.660 |
Why?
|
| Clinical Medicine | 1 | 2019 | 4 | 0.650 |
Why?
|
| Bundle of His | 1 | 2019 | 55 | 0.630 |
Why?
|
| Pulmonary Artery | 5 | 2020 | 68 | 0.630 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2018 | 29 | 0.620 |
Why?
|
| Magnetite Nanoparticles | 1 | 2018 | 15 | 0.620 |
Why?
|
| Models, Cardiovascular | 4 | 2008 | 46 | 0.620 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 346 | 0.600 |
Why?
|
| Time Factors | 12 | 2018 | 1563 | 0.580 |
Why?
|
| Sotalol | 2 | 2016 | 9 | 0.580 |
Why?
|
| Cholinergic Agonists | 1 | 2017 | 6 | 0.580 |
Why?
|
| Sick Sinus Syndrome | 1 | 2017 | 5 | 0.580 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2017 | 14 | 0.560 |
Why?
|
| Coronary Vessels | 3 | 2013 | 151 | 0.560 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2016 | 3 | 0.550 |
Why?
|
| Phenethylamines | 1 | 2016 | 5 | 0.540 |
Why?
|
| Prospective Studies | 10 | 2023 | 1216 | 0.530 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 216 | 0.530 |
Why?
|
| Inpatients | 1 | 2016 | 56 | 0.520 |
Why?
|
| Stroke Volume | 5 | 2024 | 111 | 0.510 |
Why?
|
| Spinal Cord Stimulation | 1 | 2015 | 13 | 0.510 |
Why?
|
| Sulfonamides | 1 | 2016 | 69 | 0.510 |
Why?
|
| Parasympatholytics | 3 | 2011 | 13 | 0.510 |
Why?
|
| Neuroimmunomodulation | 1 | 2015 | 5 | 0.500 |
Why?
|
| Potassium Channels, Voltage-Gated | 5 | 2001 | 9 | 0.490 |
Why?
|
| Glycogen | 1 | 2015 | 20 | 0.490 |
Why?
|
| Electrophysiology | 4 | 2012 | 150 | 0.490 |
Why?
|
| Electromagnetic Fields | 1 | 2014 | 14 | 0.490 |
Why?
|
| Heart Ventricles | 6 | 2023 | 127 | 0.480 |
Why?
|
| Double-Blind Method | 6 | 2021 | 399 | 0.460 |
Why?
|
| Heart Injuries | 1 | 2013 | 8 | 0.450 |
Why?
|
| Tachycardia, Sinus | 2 | 2017 | 8 | 0.450 |
Why?
|
| Cryosurgery | 1 | 2013 | 19 | 0.450 |
Why?
|
| Receptor, Muscarinic M2 | 2 | 2017 | 15 | 0.450 |
Why?
|
| Blood Pressure | 1 | 2015 | 351 | 0.440 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 8 | 0.420 |
Why?
|
| Inflammation | 1 | 2017 | 601 | 0.420 |
Why?
|
| Neurotransmitter Agents | 1 | 2012 | 20 | 0.420 |
Why?
|
| Neurotoxins | 2 | 2018 | 7 | 0.410 |
Why?
|
| Chromogranin A | 1 | 2012 | 3 | 0.410 |
Why?
|
| Endocardium | 1 | 2012 | 16 | 0.410 |
Why?
|
| Syncope, Vasovagal | 1 | 2012 | 5 | 0.400 |
Why?
|
| Ganglia, Parasympathetic | 1 | 2012 | 10 | 0.400 |
Why?
|
| Ventricular Function, Left | 4 | 2020 | 100 | 0.400 |
Why?
|
| Sympatholytics | 1 | 2011 | 2 | 0.390 |
Why?
|
| Peptide Fragments | 2 | 2017 | 197 | 0.390 |
Why?
|
| Nitric Oxide | 1 | 2012 | 151 | 0.390 |
Why?
|
| Propranolol | 1 | 2011 | 38 | 0.390 |
Why?
|
| Signal Transduction | 2 | 2020 | 1344 | 0.380 |
Why?
|
| Cholinergic Fibers | 1 | 2011 | 5 | 0.380 |
Why?
|
| Adrenergic Fibers | 1 | 2011 | 8 | 0.380 |
Why?
|
| Ganglionectomy | 1 | 2011 | 1 | 0.380 |
Why?
|
| Propanolamines | 3 | 2021 | 16 | 0.380 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 31 | 0.370 |
Why?
|
| Magnetics | 1 | 2010 | 14 | 0.370 |
Why?
|
| Ganglia, Sympathetic | 1 | 2010 | 8 | 0.370 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 49 | 0.350 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 980 | 0.350 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2023 | 171 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 586 | 0.340 |
Why?
|
| Tachycardia | 2 | 2022 | 72 | 0.340 |
Why?
|
| Calcium | 3 | 2020 | 231 | 0.330 |
Why?
|
| Adipose Tissue | 4 | 2020 | 179 | 0.330 |
Why?
|
| Metal Nanoparticles | 1 | 2010 | 128 | 0.320 |
Why?
|
| Models, Animal | 3 | 2014 | 129 | 0.320 |
Why?
|
| Ganglia, Spinal | 1 | 2008 | 25 | 0.320 |
Why?
|
| Retrospective Studies | 4 | 2020 | 2432 | 0.310 |
Why?
|
| Neurons | 1 | 2010 | 275 | 0.310 |
Why?
|
| Atracurium | 1 | 2008 | 3 | 0.310 |
Why?
|
| Stroke | 3 | 2023 | 233 | 0.300 |
Why?
|
| Cardiac Catheterization | 5 | 2020 | 112 | 0.280 |
Why?
|
| Adult | 8 | 2018 | 7384 | 0.280 |
Why?
|
| Ganglia | 1 | 2006 | 9 | 0.280 |
Why?
|
| Nanoparticles | 1 | 2010 | 273 | 0.280 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2006 | 20 | 0.270 |
Why?
|
| Quinidine | 2 | 2011 | 5 | 0.260 |
Why?
|
| Injections | 3 | 2021 | 31 | 0.260 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 747 | 0.260 |
Why?
|
| Epicardial Mapping | 2 | 2019 | 8 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 243 | 0.240 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 472 | 0.240 |
Why?
|
| Disease Progression | 2 | 2018 | 450 | 0.240 |
Why?
|
| Myocardium | 5 | 2002 | 171 | 0.230 |
Why?
|
| Ventricular Premature Complexes | 1 | 2023 | 5 | 0.230 |
Why?
|
| Proof of Concept Study | 2 | 2021 | 11 | 0.220 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 508 | 0.220 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 33 | 0.220 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 125 | 0.220 |
Why?
|
| Electric Countershock | 2 | 2018 | 29 | 0.220 |
Why?
|
| Recurrence | 4 | 2018 | 316 | 0.210 |
Why?
|
| Mitral Valve Prolapse | 1 | 2022 | 21 | 0.210 |
Why?
|
| Heart Valve Diseases | 1 | 2022 | 26 | 0.210 |
Why?
|
| Risk Factors | 4 | 2016 | 2010 | 0.200 |
Why?
|
| Equipment Design | 3 | 2020 | 211 | 0.200 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2001 | 6 | 0.200 |
Why?
|
| Cation Transport Proteins | 2 | 2000 | 54 | 0.200 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2012 | 43 | 0.200 |
Why?
|
| Tachycardia, Paroxysmal | 2 | 2013 | 7 | 0.200 |
Why?
|
| Amiodarone | 1 | 2021 | 11 | 0.190 |
Why?
|
| Drug Utilization | 1 | 2021 | 28 | 0.180 |
Why?
|
| Endarterectomy | 1 | 2020 | 4 | 0.180 |
Why?
|
| Adiponectin | 1 | 2020 | 29 | 0.180 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 30 | 0.180 |
Why?
|
| Ear, External | 1 | 2020 | 11 | 0.170 |
Why?
|
| Metformin | 1 | 2020 | 32 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2020 | 62 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2020 | 128 | 0.170 |
Why?
|
| Pyrimidines | 1 | 2020 | 121 | 0.170 |
Why?
|
| Coronary Sinus | 1 | 2019 | 4 | 0.170 |
Why?
|
| Anniversaries and Special Events | 1 | 2019 | 3 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 126 | 0.160 |
Why?
|
| Magnesium | 1 | 1999 | 40 | 0.160 |
Why?
|
| Adolescent | 2 | 2018 | 2957 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2009 | 65 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2019 | 83 | 0.160 |
Why?
|
| Cytokines | 2 | 2020 | 439 | 0.160 |
Why?
|
| Atrial Septum | 1 | 2018 | 2 | 0.160 |
Why?
|
| Membrane Potentials | 5 | 2001 | 61 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2018 | 76 | 0.150 |
Why?
|
| Trans-Activators | 1 | 1999 | 113 | 0.150 |
Why?
|
| Atrial Flutter | 1 | 2018 | 13 | 0.150 |
Why?
|
| Methylamines | 1 | 2018 | 6 | 0.150 |
Why?
|
| Oxidants | 1 | 2018 | 30 | 0.150 |
Why?
|
| Quality of Life | 2 | 2023 | 463 | 0.150 |
Why?
|
| Optogenetics | 1 | 2017 | 6 | 0.150 |
Why?
|
| Benzazepines | 1 | 2017 | 12 | 0.150 |
Why?
|
| Rabbits | 2 | 2015 | 272 | 0.150 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2017 | 8 | 0.150 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 14 | 0.140 |
Why?
|
| Electrodes, Implanted | 2 | 2007 | 40 | 0.140 |
Why?
|
| Fluoroscopy | 1 | 2017 | 34 | 0.140 |
Why?
|
| Drug Interactions | 1 | 2017 | 77 | 0.140 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2017 | 52 | 0.140 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2017 | 34 | 0.140 |
Why?
|
| In Vitro Techniques | 2 | 2012 | 239 | 0.140 |
Why?
|
| Binding Sites | 1 | 2017 | 338 | 0.130 |
Why?
|
| Aorta | 1 | 2017 | 123 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 43 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 45 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 121 | 0.130 |
Why?
|
| Recovery of Function | 3 | 2024 | 111 | 0.130 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2015 | 8 | 0.130 |
Why?
|
| Kidney | 2 | 2014 | 275 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2017 | 189 | 0.130 |
Why?
|
| Hypertension | 1 | 2018 | 304 | 0.130 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 1926 | 0.130 |
Why?
|
| Protein Binding | 1 | 2017 | 631 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 482 | 0.120 |
Why?
|
| Secondary Prevention | 2 | 2014 | 44 | 0.120 |
Why?
|
| Coronary Angiography | 2 | 2013 | 149 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 93 | 0.120 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2012 | 26 | 0.120 |
Why?
|
| Fibrosis | 1 | 2015 | 115 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2016 | 293 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2016 | 702 | 0.110 |
Why?
|
| Reoperation | 2 | 2011 | 144 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2013 | 11 | 0.110 |
Why?
|
| Oocytes | 5 | 1999 | 24 | 0.110 |
Why?
|
| Epinephrine | 1 | 2013 | 36 | 0.110 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 152 | 0.110 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2012 | 5 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 246 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 213 | 0.110 |
Why?
|
| Adrenergic Neurons | 1 | 2012 | 3 | 0.110 |
Why?
|
| Cholinergic Neurons | 1 | 2012 | 5 | 0.110 |
Why?
|
| Exercise | 1 | 2017 | 451 | 0.100 |
Why?
|
| Microelectrodes | 1 | 2011 | 18 | 0.100 |
Why?
|
| Disopyramide | 1 | 2011 | 10 | 0.100 |
Why?
|
| Sodium Channel Blockers | 1 | 2011 | 11 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 357 | 0.100 |
Why?
|
| American Heart Association | 1 | 2011 | 21 | 0.100 |
Why?
|
| Cloning, Molecular | 5 | 1998 | 205 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2012 | 388 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 80 | 0.090 |
Why?
|
| Acrylamides | 1 | 2010 | 5 | 0.090 |
Why?
|
| Magnetic Fields | 1 | 2010 | 4 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 203 | 0.090 |
Why?
|
| Sinoatrial Node | 2 | 2008 | 16 | 0.090 |
Why?
|
| Ferric Compounds | 1 | 2010 | 43 | 0.090 |
Why?
|
| Alternative Splicing | 2 | 2001 | 44 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2011 | 93 | 0.090 |
Why?
|
| Ventricular Fibrillation | 1 | 2010 | 40 | 0.090 |
Why?
|
| Blood Gas Analysis | 1 | 2009 | 9 | 0.090 |
Why?
|
| Vagotomy | 1 | 2009 | 21 | 0.090 |
Why?
|
| Software | 1 | 2011 | 121 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2016 | 390 | 0.090 |
Why?
|
| Propafenone | 1 | 2009 | 4 | 0.080 |
Why?
|
| Cholinergic Agents | 1 | 2009 | 6 | 0.080 |
Why?
|
| Thoracotomy | 1 | 2009 | 16 | 0.080 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 7 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 70 | 0.080 |
Why?
|
| Acute Disease | 1 | 2009 | 153 | 0.080 |
Why?
|
| Protein Kinase C | 2 | 2001 | 72 | 0.080 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2008 | 2 | 0.080 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2008 | 6 | 0.080 |
Why?
|
| Isoquinolines | 1 | 2008 | 14 | 0.080 |
Why?
|
| Fourier Analysis | 1 | 2008 | 31 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 465 | 0.080 |
Why?
|
| Ion Channel Gating | 2 | 2000 | 18 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 75 | 0.070 |
Why?
|
| Shal Potassium Channels | 3 | 2001 | 3 | 0.070 |
Why?
|
| Catheterization | 1 | 2007 | 50 | 0.070 |
Why?
|
| Young Adult | 1 | 2013 | 2582 | 0.070 |
Why?
|
| Carbachol | 1 | 2006 | 18 | 0.070 |
Why?
|
| Xenopus laevis | 2 | 1999 | 47 | 0.070 |
Why?
|
| Gene Expression | 2 | 2001 | 406 | 0.070 |
Why?
|
| Patch-Clamp Techniques | 3 | 2000 | 30 | 0.060 |
Why?
|
| Biomarkers | 2 | 2020 | 733 | 0.060 |
Why?
|
| Xenopus | 3 | 1994 | 28 | 0.060 |
Why?
|
| Optics and Photonics | 1 | 2005 | 23 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 79 | 0.060 |
Why?
|
| Respiratory Rate | 1 | 2024 | 7 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2001 | 129 | 0.060 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 160 | 0.060 |
Why?
|
| Oklahoma | 2 | 2018 | 973 | 0.060 |
Why?
|
| Phorbol Esters | 2 | 2001 | 5 | 0.060 |
Why?
|
| Benzophenanthridines | 2 | 2001 | 8 | 0.060 |
Why?
|
| Alkaloids | 2 | 2001 | 16 | 0.060 |
Why?
|
| Phenanthridines | 2 | 2001 | 12 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 42 | 0.060 |
Why?
|
| Colchicine | 1 | 2023 | 15 | 0.050 |
Why?
|
| Comorbidity | 2 | 2016 | 252 | 0.050 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 1993 | 22 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 32 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 53 | 0.050 |
Why?
|
| Latin America | 1 | 2022 | 8 | 0.050 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 2 | 2000 | 4 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 69 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 472 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2023 | 96 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2001 | 560 | 0.050 |
Why?
|
| Troponin I | 1 | 2002 | 14 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 2 | 2017 | 4 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2001 | 13 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 9 | 0.050 |
Why?
|
| Defibrillators, Implantable | 1 | 2002 | 45 | 0.050 |
Why?
|
| Transfection | 4 | 2000 | 312 | 0.050 |
Why?
|
| Carcinogens | 1 | 2001 | 37 | 0.050 |
Why?
|
| Incidence | 1 | 2023 | 545 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2000 | 10 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2000 | 12 | 0.050 |
Why?
|
| Enzyme Activators | 1 | 2020 | 8 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 7 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 247 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 99 | 0.040 |
Why?
|
| Atrial Remodeling | 1 | 2020 | 3 | 0.040 |
Why?
|
| Walk Test | 1 | 2020 | 20 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 50 | 0.040 |
Why?
|
| 3T3-L1 Cells | 1 | 2020 | 27 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2020 | 59 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 72 | 0.040 |
Why?
|
| Adipocytes | 1 | 2020 | 53 | 0.040 |
Why?
|
| Ethanol | 1 | 2020 | 118 | 0.040 |
Why?
|
| ERG1 Potassium Channel | 1 | 1999 | 4 | 0.040 |
Why?
|
| Transcriptional Regulator ERG | 1 | 1999 | 10 | 0.040 |
Why?
|
| Diastole | 1 | 2018 | 22 | 0.040 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2018 | 12 | 0.040 |
Why?
|
| Rats, Inbred Dahl | 1 | 2018 | 15 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1999 | 100 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 278 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 12 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 148 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 11 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 22 | 0.040 |
Why?
|
| China | 1 | 2017 | 53 | 0.040 |
Why?
|
| Myoglobin | 1 | 2017 | 32 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 545 | 0.040 |
Why?
|
| Echocardiography | 1 | 2017 | 107 | 0.040 |
Why?
|
| Cell Line | 1 | 1999 | 672 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 1998 | 646 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 218 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2015 | 22 | 0.030 |
Why?
|
| Rats | 3 | 1993 | 1545 | 0.030 |
Why?
|
| Mutation | 1 | 1999 | 820 | 0.030 |
Why?
|
| United States | 2 | 2011 | 2031 | 0.030 |
Why?
|
| Brain | 1 | 2019 | 699 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2013 | 32 | 0.030 |
Why?
|
| Tomography, Spiral Computed | 1 | 2013 | 8 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 4406 | 0.030 |
Why?
|
| Tetraethylammonium Compounds | 1 | 1993 | 1 | 0.030 |
Why?
|
| Tetraethylammonium | 1 | 1993 | 2 | 0.030 |
Why?
|
| Macromolecular Substances | 1 | 1993 | 52 | 0.030 |
Why?
|
| Models, Chemical | 1 | 1993 | 88 | 0.030 |
Why?
|
| Computer Simulation | 1 | 1993 | 221 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 408 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 367 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 63 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2011 | 49 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2000 | 970 | 0.020 |
Why?
|
| DNA | 1 | 1992 | 365 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 54 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 225 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 759 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 34 | 0.020 |
Why?
|
| Phrenic Nerve | 1 | 2007 | 22 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2007 | 57 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2007 | 228 | 0.020 |
Why?
|
| Ryanodine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Tetrodotoxin | 1 | 2005 | 12 | 0.020 |
Why?
|
| Atenolol | 1 | 2005 | 10 | 0.020 |
Why?
|
| Pyridinium Compounds | 1 | 2005 | 8 | 0.020 |
Why?
|
| Fluorescence | 1 | 2005 | 48 | 0.020 |
Why?
|
| Photons | 1 | 2005 | 27 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2007 | 259 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2005 | 67 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 88 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1998 | 674 | 0.010 |
Why?
|
| Linear Models | 1 | 2005 | 201 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2004 | 19 | 0.010 |
Why?
|
| Isoproterenol | 1 | 2004 | 23 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 28 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 205 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1998 | 1036 | 0.010 |
Why?
|
| Electrodes | 1 | 2004 | 71 | 0.010 |
Why?
|
| Drosophila | 2 | 1993 | 32 | 0.010 |
Why?
|
| Diverticulum | 1 | 2002 | 6 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 16 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2002 | 13 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 86 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 298 | 0.010 |
Why?
|
| Kv1.4 Potassium Channel | 1 | 2000 | 1 | 0.010 |
Why?
|
| Ion Transport | 1 | 2000 | 11 | 0.010 |
Why?
|
| Cadmium | 1 | 2000 | 14 | 0.010 |
Why?
|
| Markov Chains | 1 | 2000 | 16 | 0.010 |
Why?
|
| Potassium | 1 | 2000 | 41 | 0.010 |
Why?
|
| CHO Cells | 1 | 2000 | 96 | 0.010 |
Why?
|
| Sodium | 1 | 2000 | 47 | 0.010 |
Why?
|
| Cricetinae | 1 | 2000 | 129 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2000 | 88 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2000 | 38 | 0.010 |
Why?
|
| Reaction Time | 1 | 2000 | 94 | 0.010 |
Why?
|
| Arthrography | 1 | 1960 | 1 | 0.010 |
Why?
|
| Musculoskeletal System | 1 | 1960 | 6 | 0.010 |
Why?
|
| Temporomandibular Joint | 1 | 1960 | 16 | 0.010 |
Why?
|
| Internet | 1 | 2000 | 121 | 0.010 |
Why?
|
| Genes | 1 | 1998 | 35 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 76 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 131 | 0.010 |
Why?
|
| Genome, Human | 1 | 1998 | 71 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1998 | 229 | 0.010 |
Why?
|
| Staurosporine | 1 | 1994 | 10 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1994 | 262 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1994 | 235 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 1993 | 39 | 0.010 |
Why?
|
| RNA | 1 | 1993 | 105 | 0.010 |
Why?
|
| Phenotype | 1 | 1994 | 667 | 0.010 |
Why?
|
| X-Rays | 1 | 1960 | 29 | 0.000 |
Why?
|